David P Steensma
Steensma, David P.
VIAF ID: 315218942 (Personal)
Permalink: http://viaf.org/viaf/315218942
Preferred Forms
- 100 0 _ ‡a David P Steensma
- 100 1 _ ‡a Steensma, David P.
- 100 1 _ ‡a Steensma, David P.
- 100 1 _ ‡a Steensma, David P.
-
-
-
- 100 1 _ ‡a Steensma, David P.
-
4xx's: Alternate Name Forms (4)
Works
Title | Sources |
---|---|
Carbonated soft drinks : formulation and manufacture | |
Hoffbrand's essential haematology | |
Myelodysplastic syndromes, 2008: | |
Niedokrwistość w wieku podeszłym | |
Oddballs: acute leukemias of mixed phenotype and ambiguous origin. | |
On the TRAIL of a new therapy for leukemia. | |
Oncologists' Reluctance to Use the Terms Hope and Cure: A Bibliometric Analysis of Articles From Two High-Impact Oncology Journals | |
Oral cedazuridine/decitabine: a phase 2, pharmacokinetic/pharmacodynamic, randomized, crossover study in MDS and CMML | |
Out of this nettle, danger, we must pluck this flower, safety | |
Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission | |
Outdated dogma? Busulfan, seizure prophylaxis, and stem cell allografting | |
Overcoming obstacles to hospice care: an ethical examination of inertia and inaction | |
The Patient Protection and Affordable Care Act: Is it good or bad for oncology? | |
Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia | |
Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia | |
Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer | |
Physician-poet William Carlos Williams--"no ideas but in things". | |
Platelet count is an IPSS-independent risk factor predicting survival in refractory anaemia with ringed sideroblasts | |
Platelet pathology in sex-linked GATA-1 dyserythropoietic macrothrombocytopenia II. Cytochemistry | |
Polycythemia vera: plethora, from prehistory to present. | |
Polyradiculopathy due to methotrexate-induced ebv-associated lymphoproliferative disorder | |
Prevalence of erythrocyte haemoglobin H inclusions in unselected patients with clonal myeloid disorders | |
Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases | |
Prince Wongsa Dhiraj Snid--Thai physician and diplomat | |
Processes to activate phase III clinical trials in a cooperative oncology group: the elephant is monstrous. | |
Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials | |
Prospects and perils of retrospective risk assessment of erythropoiesis-stimulating agents. | |
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice | |
Pure red cell aplasia associated with thymoma: clinical insights from a 50-year single-institution experience | |
Putting it all together in CMML risk stratification. | |
The questions of prognosis. | |
Reassurance | |
Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not. | |
Reply to H. Kantarjian et al. | |
Review: epoetin and darbepoetin reduce need for blood transfusions but increase risk for thrombosis in patients with cancer. | |
An RNA bestiary in splicing-mutant MDS | |
The scent of cancer. | |
Serum hepcidin levels predict response to intravenous iron and darbepoetin in chemotherapy-associated anemia. | |
Severe coagulation factor V deficiency associated with an interstitial deletion of chromosome 1q | |
Should oncologists support the Affordable Care Act? | |
Sidney Altman--Nobel laureate for work with RNA | |
Speaking a common language in MDS/MPNs. | |
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts | |
Splenic histopathological patterns in chronic myelomonocytic leukemia with clinical correlations: reinforcement of the heterogeneity of the syndrome | |
Stamp vignette on medical science. William F. Giauque--Nobel Prize for low-temperature research | |
Stories we tell one another: narrative reflection and the art of oncology. | |
Stress-induced hematopoietic failure in the absence of immediate early response gene X-1 (IEX-1, IER3) | |
Submitting to Autonomy | |
Susumu Tonegawa--Japan's first Nobel laureate in physiology or medicine | |
The symbol of modern medicine | |
Symptom control trials: a 20-year experience. | |
VTE and mortality associated with erythropoiesis-stimulating agents in cancer-associated anemia | |
Walter Hess—Nobel Prize for work on the brain | |
The well-being and personal wellness promotion strategies of medical oncologists in the North Central Cancer Treatment Group. | |
What To Tell Your Patient With Clonal Hematopoiesis And Why: Insights From Two Specialized Clinics | |
Why does my patient have lymphadenopathy or splenomegaly? | |
Why me? | |
Wilberforce J. J. Arnold--"St. Helena's Greatest Friend". | |
William Murphy--Nobel Prize for the treatment of pernicious anemia. | |
Working against the grain |